• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    73 Biggest Movers From Yesterday

    5/17/22 4:49:25 AM ET
    $ACLX
    $ADMP
    $AEZS
    $AGRI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACLX alert in real time by email

    Gainers

    • AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
    • NewAge, Inc. (NASDAQ:NBEV) gained 65.8% to settle at $0.4245.
    • Data Storage Corporation (NASDAQ:DTST) shares climbed 50% to close at $3.45 on Monday after the company reported better-than-expected Q1 financial results.
    • Trevena, Inc. (NASDAQ:TRVN) rose 49.2% to settle at $0.3028. Trevena recently posted a Q1 loss of $0.10 per share.
    • Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) jumped 39% to close at $0.2978. Corbus Pharmaceuticals recently posted a Q1 loss of $0.08 per share.
    • Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) rose 29.2% to settle at $2.21. Xeris Pharmaceuticals recently posted a Q1 loss of $0.25 per share.
    • Aspira Women's Health Inc. (NASDAQ:AWH) jumped 28.6% to close at $0.58. Aspira Womens Health recently posted a Q1 loss of $0.08 per share.
    • Indonesia Energy Corporation Limited (NYSE:INDO) gained 27.1% to close at $17.54.
    • High Tide Inc. (NASDAQ:HITI) surged 26.7% to settle at $2.28.
    • Pulse Biosciences, Inc. (NASDAQ:PLSE) rose 26.5% to close at $2.15. Pulse Biosciences recently posted a Q1 loss of $0.58 per share.
    • Arcadia Biosciences, Inc. (NASDAQ:RKDA) jumped 24.8% to settle at $1.26. Arcadia Biosciences recently reported better-than-expected Q1 EPS and sales results.
    • Crexendo, Inc. (NASDAQ:CXDO) gained 24.6% to close at $2.99. Crexendo recently posted Q1 EPS of $0.02.
    • ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) rose 24.6% to settle at $3.50.
    • Carver Bancorp, Inc. (NASDAQ:CARV) gained 24.2% to close at $10.06.
    • ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) climbed 24.6% to close at $3.50. ORIC Pharmaceuticals recently posted a Q1 loss of $0.59 per share.
    • Griffon Corporation (NYSE:GFF) gained 23.9% to close at $30.13. Griffon announced review of strategic alternatives.
    • Vigil Neuroscience, Inc. (NASDAQ:VIGL) rose 23.9% to close at $2.85. Vigil Neuroscience posted a Q1 loss of $0.58 per share.
    • Clever Leaves Holdings Inc. (NASDAQ:CLVR) gained 22.6% to settle at $1.30. Clever Leaves recently reported its financial and operating results for the first quarter ended March 31, 2022.
    • Creative Realities, Inc. (NASDAQ:CREX) surged 22.3% to close at $0.85. Creative Realities posted Q1 sales of $10.80 million.
    • Benson Hill, Inc. (NYSE:BHIL) climbed 21.6% to close at $3.66 following strong quarterly results.
    • Cabaletta Bio, Inc. (NASDAQ:CABA) rose 21.5% to close at $1.81.
    • RiceBran Technologies (NASDAQ:RIBT) gained 21.2% to close at $0.63.
    • Sundial Growers Inc. (NASDAQ:SNDL) climbed 21.1% to close at $0.4650. Delta 9 Cannabis released financial and operating results for the three-month period ending March 31, 2022, reporting net revenue of $12.5 million.
    • Applied Blockchain, Inc. (NASDAQ:APLD) gained 21.2% to close at $2.18. Applied Blockchain posted a Q3 loss of $0.12 per share.
    • Ontrak, Inc. (NASDAQ:OTRK) rose 21% to settle at $1.67. Ontrak recently issued FY22 sales guidance below analyst estimates.
    • Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) gained 20.7% to close at $0.4646. Adamis Pharmaceuticals posted Q1 sales of $1.20 million.
    • Eargo, Inc. (NASDAQ:EAR) jumped 20.3% to close at $1.54. Eargo received Nasdaq notice of non-compliance related to filing of the company’s 10-Q, 10-K.
    • Eve Holding, Inc. (NYSE:EVEX) rose 20.2% to settle at $7.63.
    • Urban One, Inc. (NASDAQ:UONE) gained 19.8% to close at $11.26.
    • Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) rose 18.9% to close at $24.41. Zentalis Pharmaceuticals priced 10,330,000 share common stock offering at $19.38 per share.
    • Tidewater Inc. (NYSE:TDW) climbed 17.3% to close at $24.96.
    • ManTech International Corporation (NASDAQ:MANT) climbed 15% to close at $94.29. Carlyle announced plans to acquire ManTech in all-cash transaction valued at $4.2 billion.
    • iQIYI, Inc. (NASDAQ:IQ) shares rose 14.8% to close at $3.41. JP Morgan upgraded iQIYI from Underweight to Overweight and raised the price target from $2 to $8.
    • Rattler Midstream LP (NASDAQ:RTLR) rose 14.2% to close at $14.67 after Diamondback Energy announced it would acquire publicly held shares of Rattler Midstream for 0.113 shares of Diamondback Energy.
    • Greenland Technologies Holding Corporation (NASDAQ:GTEC) rose 14.1% to settle at $3.15. Greenland Technologies reported a first-quarter FY22 revenue increase of 19% to $29.3 million, beating the consensus of $24.36 million.
    • Spirit Airlines, Inc. (NYSE:SAVE) shares rose 13.5% to close at $19.27 after JetBlue appealed directly to Spirit shareholders for consideration of JetBlue's acquisition offer of the company at $30 per share.
    • Teekay Tankers Ltd. (NYSE:TNK) jumped 13.1% to close at $18.08. The company recently released quarterly results.
    • Clear Secure, Inc. (NYSE:YOU) gained 12.7% to settle at $31.85 after the company announced better-than-expected financial expectations for the upcoming quarter and announced a $100M buyback plan.
    • Nephros, Inc. (NASDAQ:NEPH) climbed 10.7% to close at $2.27. Nephros recently reported worse-than-expected Q1 EPS and sales results and withdrew its FY22 revenue guidance.
    • CorMedix Inc. (NASDAQ:CRMD) gained 10.4% to close at $3.61. CorMedix recently reported better-than-expected Q1 EPS results.
    • Verb Technology Company, Inc. (NASDAQ:VERB) gained 10% to close at $0.3279.
    • Fast Radius, Inc. (NASDAQ:FSRD) rose 7.2% to settle at $0.6249. Needham maintained Fast Radius with a Buy and lowered the price target from $4 to $3.


    Losers

    • Chimerix, Inc. (NASDAQ:CMRX) shares tumbled 60.9% to close at $1.66 on Monday. Emergent BioSolutions Inc (NYSE:EBS) agreed to acquire Chimerix’s exclusive worldwide rights to Tembexa (brincidofovir), the first FDA-approved antiviral for all age groups for smallpox.
    • Predictive Oncology Inc. (NASDAQ:POAI) declined 45.8% to settle at $0.3787 after the company announced $7.2 million registered direct offerings.
    • Forge Global Holdings, Inc. (NYSE:FRGE) fell 37.7% to close at $17.49. After the closing bell, Forge Global reported first-quarter revenue of $20.02 million, which was down from revenue of $32.06 million in the prior year quarter.
    • Iris Energy Limited (NASDAQ:IREN) shares dropped 36.5% to close at $4.90 after jumping around 17% on Friday. The company recently posted downbeat quarterly sales.
    • Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) fell 31.4% to settle at $0.0904. Tonix Pharmaceuticals reported a 1-for-32 reverse stock split.
    • Blue Water Vaccines, Inc. (NASDAQ:BWV) dipped 27.6% to close at $4.10. Blue Water Vaccines reported a Q1 loss of $0.34 per share.
    • Pintec Technology Holdings Limited (NASDAQ:PT) fell 26.5% to close at $1.71.
    • FedNat Holding Company (NASDAQ:FNHC) dipped 25.1% to close at $0.3415. FedNat recently reported worse-than-expected Q1 adjusted EPS and sales results.
    • Eliem Therapeutics, Inc. (NASDAQ:ELYM) fell 23.4% to close at $3.37 after the company reported a Q1 loss of $0.50 per share.
    • ShiftPixy, Inc. (NASDAQ:PIXY) fell 23.1% to $0.3921 after jumping 155% on Friday.
    • Lucira Health, Inc. (NASDAQ:LHDX) dropped 22.9% to close at $2.05. Lucira Health recently posted Q1 adjusted net income of $16.668 million.
    • Aeterna Zentaris Inc. (NASDAQ:AEZS) fell 22.7% to settle at $0.1895.
    • SQL Technologies Corp. (NASDAQ:SKYX) dipped 22.2% to close at $4.21.
    • ToughBuilt Industries, Inc. (NASDAQ:TBLT) fell 21.9% to close at $7.44.
    • Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) declined 20.7% to close at $0.5552.
    • Valneva SE (NASDAQ:VALN) fell 20.6% to settle at $19.80. Valneva warned it might have to reconsider its FY22 financial guidance after the European Commission informed the company of its intent to terminate an advance purchase agreement (APA) for its VLA2001 COVID-19 candidate vaccine.
    • PolarityTE, Inc. (NASDAQ:PTE) fell 19.4% to close at $0.1706 after jumping around 45% on Friday. The U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to PolarityTE’s SkinTE under the its open investigational new drug application (IND).
    • Aprea Therapeutics, Inc. (NASDAQ:APRE) declined 19.1% to settle at $0.9628. Aprea Therapeutics posted a Q1 loss of $0.36 per share.
    • Inhibrx, Inc. (NASDAQ:INBX) declined 19% to close at $13.73. Inhibrx announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (AATD).
    • Actelis Networks, Inc. (NASDAQ:ASNS) fell 18.8% to close at $1.95. The company recently priced its IPO at $4 per share.
    • MedAvail Holdings, Inc. (NASDAQ:MDVL) dipped 18.7% to settle at $1.70. The company recently posted upbeat quarterly sales.
    • Datasea Inc. (NASDAQ:DTSS) declined 17.9% to settle at $1.84 after the company reported Q3 earnings results.
    • Alpha Teknova, Inc. (NASDAQ:TKNO) dropped 17.7% to close at $10.59.
    • Berkshire Grey, Inc. (NASDAQ:BGRY) fell 15.8% to settle at $2.03.
    • Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares fell 15.4% to close at $0.38 after gaining around 9% on Friday. Akebia Therapeutics posted a Q1 loss of $0.35 per share.
    • Humacyte, Inc. (NASDAQ:HUMA) fell 15.1% to close at $4.56. Humacyte posted a Q1 loss of $0.19 per share.
    • Cyngn Inc. (NASDAQ:CYN) fell 14.9% to close at $2.80.
    • Arcellx, Inc. (NASDAQ:ACLX) declined 14.6% to settle at $7.61. Arcellx recently posted a Q1 loss of $1.56 per share.
    • InnovAge Holding Corp. (NASDAQ:INNV) dipped 11.7% to close at $4.53. Baird downgraded InnovAge Holding from Outperform to Neutral and lowered the price target from $6 to $5.
    • Nu Holdings Ltd. (NYSE:NU) fell 9.8% to close at $4.35.
    • Diebold Nixdorf, Incorporated (NYSE:DBD) fell 9.3% to close at $3.22 after jumping 15% on Friday.
    Get the next $ACLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACLX
    $ADMP
    $AEZS
    $AGRI

    CompanyDatePrice TargetRatingAnalyst
    Pulse Biosciences Inc
    $PLSE
    1/30/2026$25.00Outperform
    Mizuho
    IREN Limited
    $IREN
    1/13/2026$80.00Sell → Buy
    H.C. Wainwright
    Arcellx Inc.
    $ACLX
    1/7/2026$100.00Buy
    UBS
    Oric Pharmaceuticals Inc.
    $ORIC
    1/7/2026$22.00Overweight
    Piper Sandler
    Arcellx Inc.
    $ACLX
    12/22/2025$100.00Overweight
    Wells Fargo
    IREN Limited
    $IREN
    12/18/2025$39.00Neutral
    Goldman
    Forge Global Holdings Inc.
    $FRGE
    12/12/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Clear Secure Inc.
    $YOU
    12/12/2025$42.00Neutral → Overweight
    Analyst
    More analyst ratings

    $ACLX
    $ADMP
    $AEZS
    $AGRI
    SEC Filings

    View All

    Arcadia Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)

    2/6/26 4:03:58 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form 10-Q filed by IREN Limited

    10-Q - IREN Ltd (0001878848) (Filer)

    2/5/26 4:08:45 PM ET
    $IREN
    EDP Services
    Technology

    SEC Form 424B5 filed by Indonesia Energy Corporation Limited

    424B5 - Indonesia Energy Corp Ltd (0001757840) (Filer)

    2/5/26 4:08:40 PM ET
    $INDO
    Oil & Gas Production
    Energy

    $ACLX
    $ADMP
    $AEZS
    $AGRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/CEO Gilad Oren bought $25,009 worth of shares (28,100 units at $0.89), increasing direct ownership by 8% to 373,720 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:08:08 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought $5,073 worth of shares (5,700 units at $0.89), increasing direct ownership by 21% to 33,433 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:05:34 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Chang David J. bought $19,888 worth of shares (8,800 units at $2.26) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:58 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    $ADMP
    $AEZS
    $AGRI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 2, 2026 (the "Grant Date"), ORIC granted a total of 173,800 non-qualified stock options and 28,700 restricted stock units to three new non-executive employees who began their employment with ORIC in January 2026. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. Th

    2/6/26 4:30:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SKYX Announces Launch at Home Depot of its Ceiling Plug & Play SKYFAN & TURBO HEATER, including a Launch of a Dedicated SkyPlug Branding Page at HomeDepot.com

    The New SkyPlug Dedicated Brand Page for SKYX's Product on HomeDepot.com Supports Product Education, Awareness, and Scalable Growth Company Anticipates Significant Growth for its Turbo Heater and Ceiling Fan Models in Home Depot Channel During 2026 Launch Expands SKYX's Retail Footprint and Positions the Company for Increased Consumer Reach in 2026 The Ceiling Fan and Space Heater Categories Represent a Multi-Billion-Dollar Annual Market in North America MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ:SKYX) (d/b/a SKYX Technologies) (the "Company" or "SKYX"), a highly disruptive smart home platform technology company with over 100 pending and issued patent

    2/6/26 9:28:14 AM ET
    $SKYX
    Building Products
    Consumer Discretionary

    Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

    Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study. The study demonstrates successful treatment of atrial fibrillation in 150 patients with rapid procedure times and minimal adverse effects. The data were presented today at the 31st Annual AF Symposium 2026 meeting, taking place February 5-7, 2026, in Boston, MA. Key study findings include: 100% procedural success of

    2/5/26 7:00:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $ACLX
    $ADMP
    $AEZS
    $AGRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Pulse Biosciences with a new price target

    Mizuho initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $25.00

    1/30/26 6:44:12 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    IREN Limited upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded IREN Limited from Sell to Buy and set a new price target of $80.00

    1/13/26 10:45:18 AM ET
    $IREN
    EDP Services
    Technology

    UBS resumed coverage on Arcellx with a new price target

    UBS resumed coverage of Arcellx with a rating of Buy and set a new price target of $100.00

    1/7/26 9:34:38 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACLX
    $ADMP
    $AEZS
    $AGRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Zelnick Kaufman Beth was granted 36,006 shares, increasing direct ownership by 15% to 269,108 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    2/6/26 9:30:06 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Todisco Joseph was granted 77,156 shares, increasing direct ownership by 11% to 774,749 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    2/6/26 9:30:03 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Hurlburt Elizabeth was granted 36,006 shares, increasing direct ownership by 15% to 278,539 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    2/6/26 9:30:04 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $ADMP
    $AEZS
    $AGRI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    November 17, 2023 - FDA Roundup: November 17, 2023

    For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

    11/17/23 4:18:44 PM ET
    $BMY
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEFENCATH issued to CORMEDIX INC

    Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    11/15/23 9:53:06 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $ADMP
    $AEZS
    $AGRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Carver Bancorp Inc.

    SC 13D/A - CARVER BANCORP INC (0001016178) (Subject)

    12/12/24 5:00:53 PM ET
    $CARV
    Savings Institutions
    Finance

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Spirit Airlines Inc.

    SC 13G - Spirit Airlines, Inc. (0001498710) (Subject)

    12/6/24 9:37:58 AM ET
    $SAVE
    Air Freight/Delivery Services
    Consumer Discretionary

    $ACLX
    $ADMP
    $AEZS
    $AGRI
    Leadership Updates

    Live Leadership Updates

    View All

    Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

    DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy joins Aprea at an important time, following the Company's recent early clinical proof-of-concept demonstrated in its ongoing Phase 1 dose-escalation study evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. He is a highly accomplished physician scientist and biopharmaceutical executive wit

    2/4/26 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Data Storage Corporation Announces Strategic Advisory Appointments, Launches New Website, and Provides Business Update on Future Strategy

    MELVILLE, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Data Storage Corporation (NASDAQ:DTST) ("Data Storage" or the "Company"), today announced the appointment of a group of experienced strategic advisors to support the execution of its post-tender offer strategy and the launch of a newly redesigned corporate website. The Company also provided a business update as it advances its next phase of growth. The advisory team has been assembled to assist management execute its strategy centered on acquiring and supporting technology-enabled service businesses with high margins, recurring revenue, and attractive valuation profiles, while remaining selective in evaluating strategic investments that

    1/14/26 8:30:00 AM ET
    $DTST
    EDP Services
    Technology

    ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

    Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose Raised $244 million from top-tier healthcare specialist funds; Cash and investments of $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout for rinzimetostat Phase 3 study Expect to report multiple cli

    1/12/26 8:30:00 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACLX
    $ADMP
    $AEZS
    $AGRI
    Financials

    Live finance-specific insights

    View All

    IREN Reports Q2 FY26 Results

    $3.6bn GPU Financing Secured for Microsoft Contract1 Targeted 140k GPU Expansion on Track to Deliver $3.4bn ARR by End of CY262 New 1.6GW Data Center Campus in Oklahoma NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- IREN Limited (NASDAQ: IREN) ("IREN" or "the Company") today reported its financial results for the three months ended December 31, 2025. Highlights $3.6bn GPU financing secured for Microsoft contract1 Interest rate of <6% p.a.Together with Microsoft prepayment ($1.9bn) covers 95% of GPU-related capex Targeted 140k GPU expansion on track to deliver $3.4bn ARR by end of CY262 Horizon 1-4 construction progressing to scheduleBritish Columbia AI Cloud expansion ongoing, with ~$0.4

    2/5/26 4:03:29 PM ET
    $IREN
    EDP Services
    Technology

    Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, following the close of market. Teknova will host a webcast and conference call on Thursday, February 26, 2026, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this l

    2/5/26 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Griffon Corporation Announces First Quarter Results

    Griffon Corporation ("Griffon" or the "Company") (NYSE:GFF) today reported results for the fiscal 2026 first quarter ended December 31, 2025. Revenue for the first quarter totaled $649.1 million, a 3% increase compared to $632.4 million in the prior year quarter. Net income totaled $64.4 million, or $1.41 per share, compared to $70.9 million, or $1.49 per share, in the prior year quarter. Excluding all items that affect comparability from both periods, adjusted net income (a non-GAAP measure) was $66.3 million, or $1.45 per share, in the current year quarter compared to $65.9 million, or $1.39 per share, in the prior year quarter. For a reconciliation of net income to adjusted net incom

    2/5/26 7:33:00 AM ET
    $GFF
    Building Products
    Industrials